

Alejandro Amor-Coarasa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5647022/publications.pdf>

Version: 2024-02-01

27
papers

734
citations

687363

13
h-index

580821

25
g-index

28
all docs

28
docs citations

28
times ranked

971
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis and Evaluation of ¹¹ C-Labeled Triazolones as Probes for Imaging Fatty Acid Synthase Expression by Positron Emission Tomography. <i>Molecules</i> , 2022, 27, 1552.	3.8	0
2	A suitable time point for quantifying the radiochemical purity of ²²⁵ Ac-labeled radiopharmaceuticals. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 38.	3.9	15
3	Otto: a 4.04â€‰GBq (109â€‰mCi) ⁶⁸ Ge/ ⁶⁸ Ga generator, first of its kind - extended quality control and performance evaluation in the clinical production of [⁶⁸ Ga]Ga-PSMA-11. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 5.	3.9	9
4	Preclinical Evaluation of a High-Affinity Sarcophagine-Containing PSMA Ligand for ⁶⁴ Cu/ ⁶⁷ Cu-Based Theranostics in Prostate Cancer. <i>Molecular Pharmaceutics</i> , 2020, 17, 1954-1962.	4.6	28
5	3D-printed automation for optimized PET radiochemistry. <i>Science Advances</i> , 2019, 5, eaax4762.	10.3	6
6	[¹⁸ F]Fluoroethyltriazolyl Monocyclam Derivatives as Imaging Probes for the Chemokine Receptor CXCR4. <i>Molecules</i> , 2019, 24, 1612.	3.8	8
7	Albumin-Binding PSMA Ligands: Implications for Expanding the Therapeutic Window. <i>Journal of Nuclear Medicine</i> , 2019, 60, 656-663.	5.0	48
8	A Single Dose of ²²⁵ Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model. <i>Journal of Nuclear Medicine</i> , 2019, 60, 649-655.	5.0	55
9	Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1841-1851.	6.4	56
10	[¹⁸ F]RPS-544: A PET tracer for imaging the chemokine receptor CXCR4. <i>Nuclear Medicine and Biology</i> , 2018, 60, 37-44.	0.6	13
11	⁶⁶ Ga: A Novelty or a Valuable Preclinical Screening Tool for the Design of Targeted Radiopharmaceuticals?. <i>Molecules</i> , 2018, 23, 2575.	3.8	9
12	4-N-Alkanoyl and 4-N-alkyl gemcitabine analogues with NOTA chelators for ⁶⁸ -gallium labelling. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 5624-5630.	3.0	2
13	Impact of elution impurities on DOTA and NOTA labeling with two commercial ⁶⁸ Ge/ ⁶⁸ Ga generators. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2018, 317, 1485-1490.	1.5	2
14	Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1442-1449.	5.0	61
15	An Eighteenâ€‰Membered Macrocyclic Ligand for Actiniumâ€‰ ²²⁵ Targeted Alpha Therapy. <i>Angewandte Chemie</i> , 2017, 129, 14904-14909.	2.0	9
16	An Eighteenâ€‰Membered Macrocyclic Ligand for Actiniumâ€‰ ²²⁵ Targeted Alpha Therapy. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 14712-14717.	13.8	163
17	Continuation of comprehensive quality control of the ⁶⁸ Ge/ ⁶⁸ Ga generator and production of ⁶⁸ Ga-DOTATOC and ⁶⁸ Ga-PSMA-HBED-CC for clinical research studies. <i>Nuclear Medicine and Biology</i> , 2017, 53, 37-39.	0.6	8
18	Synthesis and pre-clinical evaluation of a new class of high-affinity ¹⁸ F-labeled PSMA ligands for detection of prostate cancer by PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 647-661.	6.4	44

#	ARTICLE	IF	CITATIONS
19	Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of $^{68}\text{Ga}^{3+}$, $^{111}\text{In}^{3+}$, $^{177}\text{Lu}^{3+}$ and $^{225}\text{Ac}^{3+}$. Nuclear Medicine and Biology, 2017, 55, 38-46.	0.6	27
20	Comprehensive Quality Control of the ITG $^{68}\text{Ge}/^{68}\text{Ga}$ Generator and Synthesis of ^{68}Ga -DOTATOC and ^{68}Ga -PSMA-HBED-CC for Clinical Imaging. Journal of Nuclear Medicine, 2016, 57, 1402-1405.	5.0	41
21	Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors. JCI Insight, 2016, 1, e90064.	5.0	70
22	Synthesis of ^{11}C palmitic acid for PET imaging using a single molecular sieve 13X cartridge for reagent trapping, radiolabeling and selective purification. Nuclear Medicine and Biology, 2015, 42, 685-690.	0.6	7
23	^{90}Y -DOTA-CHS Microspheres for Live Radiomicrosphere Therapy: Preliminary In Vivo Lung Radiochemical Stability Studies. Journal of Radiotherapy, 2014, 2014, 1-6.	0.2	5
24	Lyophilized Kit for the Preparation of the PET Perfusion Agent [^{68}Ga]-MAA. International Journal of Molecular Imaging, 2014, 2014, 1-7.	1.3	18
25	$^{99\text{m}}\text{Tc}$ -MAA vs. ^{68}Ga -MAA as Perfusion Agents. , 2013, , .		2
26	Spectroscopic, radiochemical, and theoretical studies of the Ga^{3+} -N-(2-hydroxyethyl)piperazine- N -ethanesulfonic acid (HEPES buffer) system: evidence for the formation of Ga^{3+} -HEPES complexes in ^{68}Ga labeling reactions. Contrast Media and Molecular Imaging, 2013, 8, 265-273. http://dx.doi.org/10.1007/s11307-013-0611-0	0.8	21
27	^{68}Ga -NOTA-CHSg and $^{99\text{m}}\text{Tc}$ -CHSg	1.3	4